Navigation Links
MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza
Date:9/21/2009

GAITHERSBURG, Md., Sept. 21 /PRNewswire/ -- MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million. Previous HHS orders for approximately 13 million doses of LAIV for the 2009 H1N1 strain were placed in May and July.

The vaccine received approval from the U.S. Food and Drug Administration (FDA) on Sept. 15 and is indicated for the active immunization of individuals 2-49 years of age against influenza caused by pandemic (H1N1) 2009 virus.

MedImmune's development of LAIV for this strain of H1N1 began at the end of April, when the company received the novel virus from the U.S. Centers for Disease Control and Prevention (CDC). Enough bulk vaccine to fill all orders placed by HHS has already been manufactured and about 3.4 million doses have been released by the FDA. Distribution will occur at the direction of public health authorities.

"At MedImmune, our mission is to develop and deliver medicines that change lives, and we are proud that our innovative LAIV technology may help protect the public from the threat of 2009 H1N1 influenza," said Tony Zook, president of MedImmune. "We will continue to work collaboratively with the U.S. government and public health authorities to contribute to the response to this unpredictable infectious disease."

About LAIV

LAIV is different from the injectable influenza vaccine ("flu shot") in that it contains live vaccine virus strains that are weakened so as not to cause the flu. It is delivered into the nose, where the influenza virus usually enters the body, rather than by injection. LAIV prompts the body to begin mounting an immune response after the first dose. MedImmune's influenza vaccines are currently only licensed in the United States.

Important Safety and Eligibility information for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Who may be eligible for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal?

Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is a vaccine approved for the prevention influenza disease caused by pandemic (H1N1) 2009 virus in children, adolescents and adults, from 2-49 years of age. Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal may not protect everyone who gets it. This vaccine is for intranasal administration only.

Who may not be able to get Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal?

Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is not right for everyone. This vaccine must not be given to: people with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine; people with life-threatening reactions to previous influenza vaccinations; and children and adolescents receiving aspirin or aspirin-containing therapy. Children less than 24 months of age are not eligible for this vaccine.

The following people may not be able to get Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or may be able to get it only in certain situations: people with asthma or active wheezing, or children less than 5 years of age with recurrent wheezing; people with a history of Guillain-Barre syndrome; people with a weakened immune system; people with long-term medical conditions including heart disease, kidney disease, and metabolic diseases, such as diabetes; and pregnant women.

If a patient falls into one of these groups, a health care provider will decide if Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is right for them.

What are the most common side effects of Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Most common side effects are based on studies conducted with seasonal trivalent Influenza Vaccine Live, Intranasal manufactured by MedImmune and include runny nose or nasal congestion, sore throat, and fever. For a full list of side effects, please see section 6.1 in the following product information.

For Complete Product Information please visit: http://www.medimmune.com/pdf/products/h1n1_pi.pdf

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

The Novel Influenza A (H1N1) project has been funded in whole or in part with the Federal funds from HHS/ASPR, under Contract No. HHSO100200900002I. The opinions expressed herein do not represent opinions or statements made or expressed by the U.S. Department of Health and Human Services.


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
2. MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
3. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
4. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
5. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
6. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
7. MedImmune Expands Scientific and Engineering Leadership
8. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
9. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
10. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
11. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... CA (PRWEB) , ... July 24, 2017 , ... ... financial organizations, today announced it has partnered with WALLIX to expand its ... Publication 800-171 . , There are a number of ways to address the authentication ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they have ... a pharmacist using that same scale to dispense medication. The first example is an ... illustrations show why it is important to have the right balance for the process. ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has ... sexual abuse, and how she has overcome them. “Forbidden Memories: A Memoir,” by author ... and how she has risen above. , In “Memories,” readers get a firsthand look ...
(Date:7/24/2017)... ... July 24, 2017 , ... Right now, ... , The agency is hammering out a game plan to implement changes and ... ever to affect FDA-regulated firms. The new law:, ,     Seeks ...
(Date:7/24/2017)... ... July 24, 2017 , ... “A Short Walk to the Mailbox”: a ... the creation of published author, Ed Clark. Ed Clark is a church music ... churches as a minister of music and worship leader for over fifty years. ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
(Date:7/11/2017)... WHIPPANY, N.J. , July 11, 2017  Bayer has ... across eight countries as part of its prestigious Bayer Hemophilia ... Children,s Hospital of Philadelphia and Uniformed ... are among the winners. Grant recipients were announced ... Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
Breaking Medicine Technology: